[Iovance's] lead product candidate is an adoptive cell therapy using tumor-infiltrating lymphocyte (TIL) technology being investigated for the treatment of patients with metastatic melanoma...
NEW YORK (PRWEB) March 27, 2018
Mediaplanet announces the launch of this March's edition of "Cancer Care." This campaign will showcase the innovative work being done in the world of cancer research and highlight what industry experts and patients see as potential future treatments for cancer patients.
The print component of "Cancer Care" is distributed within this weekend's edition of USA Today in New York, Boston, Chicago, Los Angeles, Houston, Nashville and Ohio markets, with a circulation of approximately 250,000 copies and an estimated readership of 750,000. The digital component is distributed nationally, through a vast social media strategy, and across a network of top news sites and partner outlets. To explore the digital version of the campaign, click here.
We are highlighting one of the supporters of the Cancer Care campaign, Iovance Biotherapeutics. Iovance Biotherapeutics, Inc. is a clinical-stage biotherapeutics company focused on the development of cancer immunotherapy products for the treatment of various cancers. The company's lead product candidate is an adoptive cell therapy using tumor-infiltrating lymphocyte (TIL) technology being investigated for the treatment of patients with metastatic melanoma, recurrent and/or metastatic squamous cell carcinoma of the head and neck, recurrent, metastatic or persistent cervical cancer, and locally advanced or metastatic non-small cell lung cancer. Iovance's TIL technology has not been approved by the Food and Drug Administration ("FDA") and its' safety and efficacy has not been determined.
TIL manufacturing at Iovance starts with isolating tumor-infiltrating lymphocytes (TIL) from a surgically resected piece of a patient's tumor. The isolated TIL, which may recognize multiple patient-specific antigens expressed by the tumor, is expanded to billions of cells. Prior to infusion of TIL, the patients are treated with non-myeloablative lymphodepletion preconditioning to remove the suppressive tumor micro-environment. Once the TIL is infused, the patients receive up to 6 doses of IL-2 to support expansion and anti-tumor activity of the TIL against the tumor. Iovance is actively recruiting patients for several investigational Phase 2 clinical trials including:
o C-144-01: a multicenter study to assess the efficacy and safety of autologous Tumor Infiltrating Lymphocytes (LN-144) for treatment of patients with metastatic melanoma
o C-145-03: a multicenter study to evaluate the efficacy and safety of autologous Tumor Infiltrating Lymphocytes (LN-145) for the treatment of patients with recurrent metastatic squamous cell carcinoma of the head and neck
o C-145-04: a multicenter study to evaluate the efficacy and safety of autologous Tumor Infiltrating Lymphocytes (LN-145) in patients with recurrent, metastatic, or persistent cervical carcinoma
o IOV-LUN-201: a multicenter study to assess the efficacy and safety of autologous Tumor Infiltrating Lymphocytes (LN-145) alone and in combination with anti-PD-L1 inhibitor durvalumab (MEDI4736) in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC)
To speak to someone about the clinical trials, please call 1-866-565-4410, option 3 or,
Email: [email protected]
The Cancer Care campaign was made possible with the financial support of Iovance Biotherapeutics. Iovance has provided payment to Mediaplanet for this press release and other clinical trial recruitment advertisements. Other supporters include EMD Serono, ImpediMed, Amgen, St. Jude Children's Hospital, the Rapunzel Project, Kidney Cancer Association, Ohio State University- the James Cancer, the Association of Pediatric Hematology / Oncology Nurses, Oncology Nursing Certification Corporation, American Association of Cancer Research, American Society of Clinical Oncology, American Society of Radiation Oncology, National Institutes of Health, Personalized Medicine Coalition, LIVESTRONG, National Coalition of Cancer Survivorship, Leukemia and Lymphoma Society and Stand Up To Cancer.
Mediaplanet is the leading independent publisher of content marketing campaigns covering a variety of topics and industries such as Health, Education, Lifestyle, Business and Technology, and Corporate Social Responsibility. We turn consumer interest into action by providing readers with motivational editorial, pairing it with relevant advertisers and distributing it within top newspapers and online platforms around the world. Please visit http://www.mediaplanet.com for more on who we are and what we do.